Argus Upgrades GlaxoSmithKline (GSK) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Novartis (NVS)/ GlaxoSmithKline (GSK) Deal Makes Strategic Sense, Says Analyst
April 22, 2014 9:12 AM EDTNovartis (NYSE: NVS) announced that it has reached a definitive agreement with GlaxoSmithKline plc (NYSE: GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Analyst Mark Clark of Deutsche Bank said the deal makes strategic sense for GlaxoSmithKline.
"In a complex, three-part inter-conditional deal, GSK will: (1) assume control of Novartis OTC business (in return for granting Novartis a 36.5% stake in the combined Consumer Health business); (2) divest its marketed... More
Novartis (NVS), Galxo (GSK) Enter Major Asset Exchange Agreement (LLY)
April 22, 2014 8:59 AM EDTNovartis (NYSE: NVS) announced that it has reached a definitive agreement with GlaxoSmithKline plc (NYSE: GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them. The two companies would also create a joint venture, combining their consumer divisions to create a world-leading consumer healthcare business. Separately, the company announced a definitive agreement with Eli Lilly and Company (NYSE:... More
